Showing 2601-2610 of 3570 results for "".
- Merz’s Xeomin Taps Teyana Taylor as Brand Partnerhttps://practicaldermatology.com/news/merzs-xeomin-taps-teyana-taylor-as-brand-partner/2461412/Teyana Taylor is the latest brand partner for Merz’z Xeomin (incobotulinumtoxinA). The U.S. partnership is a continuation of the ‘Beauty on Your Terms’ campaign for Xeomin, an FDA-approved double filtered anti-wrinkle injection to temporarily improve the appearanc
- Game Changer: Incyte’s Ruxolitinib Reverses Vitiligohttps://practicaldermatology.com/news/game-changer-incytes-ruxolitinib-reverses-vitiligo/2461392/Topical Ruxolitinib is highly effective for skin re-pigmentation in vitiligo, according to Phase III clinical trial results published in The New England Journal of Medicine. The study showed better than 75 percent improvement on face and 50 percent improvement on body fo
- Industry Vet Curtis Cluff Named President and CFO of BioPhotas Inc.https://practicaldermatology.com/news/industry-vet-curtis-cluff-named-president-and-cfo-of-biophotas-inc/2461378/Curtis Cluff is the new President and Chief Financial Officer BioPhotas Inc., manufacturers of the Celluma series of light therapy devices. In this newly created role, Mr. Cluff will report to Patrick Johnson, Chief Executive Officer and inventor of the Celluma. &quo
- Octagam 10% Performs Well in Adults with Dermatomyositishttps://practicaldermatology.com/news/octagam-10-performs-well-in-adults-with-dermatomyositis/2461376/Octapharma’s Octagam 10% [Immune Globulin Intravenous (Human)] is efficacious and well-tolerated in adults with dermatomyositis, ac
- Galderma Debuts Sensitive Skincare Facultyhttps://practicaldermatology.com/news/galderma-debuts-sensitive-skincare-faculty/2461372/Reinforcing its commitment to advancing dermatology for every skin story, Galderma has formed a global Sensitive Skincare Faculty, which will focus its efforts on helping people with sensitive skin live better lives. The Faculty will focus on three key pillars of research, innovation, and engagem
- Evommune Initiates Phase 2a Proof-of-Concept Clinical Trial of EVO101 in ADhttps://practicaldermatology.com/news/evommune-initiates-phase-2a-proof-of-concept-clinical-trial-of-evo101-in-ad/2461362/Evommune, Inc. enrolled the first patient in a Phase 2a proof-of-concept clinical trial evaluating EVO101, a novel small molecule inhibitor of interleukin 1 receptor-associated kinase 4 (IRAK4), in patients with atopic dermatitis (AD). The Phase 2a trial is a randomized, double-bl
- Ortho Dermatologics Names 2022 Aspire Higher Scholarship Recipientshttps://practicaldermatology.com/news/ortho-dermatologics-names-2022-aspire-higher-scholarship-recipients/2461356/Bausch Health Companies Inc. and its dermatology business, Ortho Dermatologics, recently named the recipients of their 2022 Aspire Higher Scholarship program. The program, which has provided a total of $918,000 in scholarships since launching in 2013, will award nine students who have been treate
- Chicken or the Egg? Unravelling the Role of Demodex in Rosaceahttps://practicaldermatology.com/news/chicken-or-the-egg-unravelling-the-role-of-demodex-in-rosacea/2461346/Researchers have long observed that microscopic mites that live as scavengers on normal human skin tend to occur in greater numbers on the faces of rosacea patients. It was unknown, however, whether the higher density of these Demodex, was a cause or an effect of this widespread disease.
- Daxxify from Revance Gets FDA Greenlighthttps://practicaldermatology.com/news/daxxify-from-revance-gets-fda-greenlight/2461331/Daxxify™ (DaxibotulinumtoxinA-lanm) from Revance is FDA approved for the temporary improvement of moderate to severe frown lines (glabellar lines) in adults. Daxxify is the first and only neuromodulator stabilized with Peptide Exchange Technology™ (PXT) and is free of both human serum
- UK Study: Psoriasis Diagnoses in Primary Care Delayed by Up to 5 Yearshttps://practicaldermatology.com/news/uk-study-psoriasis-diagnoses-in-primary-care-delayed-by-up-to-5-years/2461322/Psoriasis may be underdiagnosed in UK primary care settings, according to research out of the University of Manchester in The British Journal of General Practice. Patients who are later diagnosed with psoriasis are twice as likely to be prescribed steroid or antifungal creams t